We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: NVIDIA, Philip Morris, Sanofi, Applied Materials and Goldman Sachs
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 15, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corporation (NVDA - Free Report) , Philip Morris International Inc. (PM - Free Report) , Sanofi (SNY - Free Report) , Applied Materials, Inc. (AMAT - Free Report) and The Goldman Sachs Group, Inc. (GS - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for NVIDIA, Philip Morris and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Philip Morris and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of NVIDIA have outperformed the Zacks General Semiconductor industry over the past year (+111% vs. +58.5%). The Zacks analyst believes that NVIDIA has been benefiting from the work and learn-from-home wave due to the ongoing pandemic.
NVDA is also benefiting from strong growth in GeForce desktop and notebook Graphic Processing Units, which is boosting gaming revenues. A surge in Hyperscale demand remains a tailwind for its Data Center business. Expansion of NVIDIA GeForce NOW is expected to drive the user base. NVIDIA’s management, however, expects the pandemic to impact near-term revenues.
Philip Morris shares have gained +15% in the year to date period against the Zacks Tobacco industry’s gain of +12.3%. The Zacks analyst believes that Philip Morris has been benefiting from its pricing power, which also aided its third-quarter 2021 results. PM gained from higher pricing across most regions.
Strength in the reduced-risk products (or RRPs) category is another major positive for Philip Morris. The popularity of IQOS has also been a strong driver of growth for PM despite its short supply concerns. The global semiconductor shortage, however, remains a major headwind for Philip Morris. PM expects limited recovery in its duty-free business in the fourth quarter, as intercontinental travel remains subdued.
Shares of Sanofi have lost -9.5% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +8.2%, although things seem to be improving. The Zacks analyst believes that Dupixent has become the key top-line driver for Sanofi due to its regular label expansion.
With revenues from outside of the U.S. accelerating, and multiple approvals for new indications expected in the near future, Dupixent’s sales are expected to rise. Sanofi possesses a leading vaccine operation, which contributes significantly to its top-line. Generic competition for several of its products, however, remains a key headwind for Sanofi.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: NVIDIA, Philip Morris, Sanofi, Applied Materials and Goldman Sachs
For Immediate Release
Chicago, IL – December 15, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corporation (NVDA - Free Report) , Philip Morris International Inc. (PM - Free Report) , Sanofi (SNY - Free Report) , Applied Materials, Inc. (AMAT - Free Report) and The Goldman Sachs Group, Inc. (GS - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for NVIDIA, Philip Morris and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Philip Morris and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of NVIDIA have outperformed the Zacks General Semiconductor industry over the past year (+111% vs. +58.5%). The Zacks analyst believes that NVIDIA has been benefiting from the work and learn-from-home wave due to the ongoing pandemic.
NVDA is also benefiting from strong growth in GeForce desktop and notebook Graphic Processing Units, which is boosting gaming revenues. A surge in Hyperscale demand remains a tailwind for its Data Center business. Expansion of NVIDIA GeForce NOW is expected to drive the user base. NVIDIA’s management, however, expects the pandemic to impact near-term revenues.
(You can read the full research report on NVIDIA here >>>)
Philip Morris shares have gained +15% in the year to date period against the Zacks Tobacco industry’s gain of +12.3%. The Zacks analyst believes that Philip Morris has been benefiting from its pricing power, which also aided its third-quarter 2021 results. PM gained from higher pricing across most regions.
Strength in the reduced-risk products (or RRPs) category is another major positive for Philip Morris. The popularity of IQOS has also been a strong driver of growth for PM despite its short supply concerns. The global semiconductor shortage, however, remains a major headwind for Philip Morris. PM expects limited recovery in its duty-free business in the fourth quarter, as intercontinental travel remains subdued.
(You can read the full research report on Philip Morris here >>>)
Shares of Sanofi have lost -9.5% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +8.2%, although things seem to be improving. The Zacks analyst believes that Dupixent has become the key top-line driver for Sanofi due to its regular label expansion.
With revenues from outside of the U.S. accelerating, and multiple approvals for new indications expected in the near future, Dupixent’s sales are expected to rise. Sanofi possesses a leading vaccine operation, which contributes significantly to its top-line. Generic competition for several of its products, however, remains a key headwind for Sanofi.
(You can read the full research report on Sanofi here >>>)
Other noteworthy reports we are featuring today include Applied Materials and Goldman Sachs.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.